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Defibrillation testing is no longer routinely performed after automatic implantable car-
dioverter-defibrillator (AICD) implantation. However, certain subjects undergoing AICD
implantation may be at higher risk of undersensing of ventricular arrhythmias resulting
in potentially fatal outcomes. We present the case of a 30-year-old woman with hy-
pertrophic cardiomyopathy (HCM; ‘asymmetric septal hypertophy’ morphologic variant)
and prophylactic AICD who experienced an out of hospital cardiac arrest. AICD inter-
rogation revealed undersensing as a result of intermittent high amplitude electrograms
during an episode of ventricular fibrillation (VF). The subject underwent replacement
and repositioning of the AICD lead along with pulse generator replacement (that utilized
a different VF sensing algorithm) with appropriate sensing of VF and successful defi-
brillation testing. The presence of intermittent high amplitude electrograms during ep-
isodes of VF in AICDs using the AGC function should be recognized as a situation
that may necessitate interventions to prevent undersensing and consequent delay in
therapy.
Copyright © 2015, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Case report
A 30-year-old woman with non-obstructive hypertrophic




mons.org/licenses/by-ncmorphologic variant) received a dual-chamber automatic
implantable cardioverter defibrillator (AICD; Boston Scientific
Teligen 100) for prevention of sudden cardiac death. She was
diagnosed during family screening after her father had been
diagnosed with HCM following a ventricular fibrillation (VF)e, 40 Ruskin Ave, Ottawa K1Y 4W7, Canada. Tel.: þ1 613 761 4820.
and hosting by Elsevier B.V. This is an open access article under
-nd/4.0/).
i n d i a n p a c i n g and e l e c t r o p h y s i o l o g y j o u rn a l 1 5 ( 2 0 1 5 ) 1 2 1e1 2 4122cardiac arrest. At implant the AICD lead tip was positioned in
the right ventricular (RV) apex and the AICD was pro-
grammed with 2 treatment zones: ventricular tachycardia
(VT) zone: 188 to 240 bpm (3 bursts of anti-tachycardia pacing
(ATP), followed by 41 J shocks), VF zone: >¼240 bpm (41 J
shocks only). Ventricular sensitivity (automatic gain control
or AGC) was nominal at 0.6 mV. As per subject request defi-
brillation testing was not performed. During follow-up visits
the subject's R wave amplitudes were noted to be consis-
tently greater than 25 mV. She remained asymptomatic
during follow-up and was compliant with Metoprolol 25 mg
orally twice a day.
Approximately 18 months after her initial implant, she
suffered an out-of-hospital cardiac arrest requiring resusci-
tation by paramedics. Her arrhythmia logbook recorded 3
episodes of non-sustained VT and 4 episodes of VT within a 4-
min period at the time of the event. ATP was delivered during
2 of the VT episodes. During the final VT episode, 3 bursts of
ATP were delivered followed by 3  41 J shocks.
A segment of the AICD tracing from the final “VT” episode
is shown in Fig. 1. The tracing shows 3 recording channels-Fig. 1 e The device tracing shows 3 recording channels (atrial ch
ventricular channel (shock)). The atrial channel shows sinus ar
near-field and far-field ventricular channels shows VF undersen
(at times as high as 14 mV) are sensed appropriately (annotate
ventricular electrograms following the large electrograms are u
frequently correlate with ventricular electrogram signals in the
sufficient number of sensed beats fell in the “VT” zone (<320 matrial channel (A), near field ventricular channel (V), and a
far-field ventricular channel (shock). The atrial channel
shows sinus arrest with 1 atrial sensed (AS) beat. Close in-
spection of the near-field and far-field ventricular channels
shows VF undersensing. Although the large amplitude ven-
tricular electrograms (at times as high as 14 mV) are sensed
appropriately (annotated PVC, VT and occasionally VF), the
smaller amplitude ventricular electrograms following the
large electrograms are undersensed. These undersensed
small ventricular signals frequently correlate with ventricu-
lar electrogram signals in the far-field shock-channel con-
firming their presence. After a sufficient number of sensed
beats fell in the “VT” zone (<320 ms), the device administered
“VT” therapy. Following 3 bursts of ATP and 2 unsuccessful
41 J shocks, a third AICD shock converted her back to sinus
rhythm. The total duration of this “VT” episode was 1 min
15 s.
Ventricular pacing thresholdwas 0.9 V@ 0.5ms and sensed
R waves were noted to be > 25 mV. Lead impedances were
normal. Defibrillation testing was performed in hospital and
VF was induced with the AGC lowered to 0.3 mV.annel (A), near field ventricular channel (V), and a far-field
rest with 1 atrial sensed (AS) beat. Close inspection of the
sing. Although the large amplitude ventricular electrograms
d PVC, VT and occasionally VF), the smaller amplitude
ndersensed. These undersensed small ventricular signals
far-field shock-channel confirming their presence. After a
s), the device administered “VT” therapy.
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unsuccessful in defibrillating the subject.Discussion
We report a case of VF undersensing and high defibrillation
thresholds in a subject with HCM with a current generation
AICD. VF was misclassified as “VT” which delayed AICD
shocks. Subsequent induction of VF during defibrillation
testing confirmed undersensing of VF and high defibrillation
thresholds.
An understanding of how AICDs sense ventricular ar-
rhythmias is required to explain the undersensing noted in
our case. Mostmanufacturers have developed algorithms that
measure R-wave amplitude on a beat-to-beat basis. These
algorithms are designed to detect small depolarization waves
during VF and to prevent T-wave oversensing during VT. In a
Boston scientific device, the algorithm is called “Automatic
Gain Control” or “AGC”. The sensing threshold is set at 75% of
the sensed R-wave height, which declines over a pre-
determined time constant. The algorithm was non-
programmable in the Boston-Scientific device used in our
subject. In our subject, large alternation of voltages during VF
led to undersensing of smaller amplitude signals immediately
following the larger signals. Lowering the AGC to 0.3 mV
proved to be insufficient for preventing undersensing in our
subject. We speculate that HCM might have been responsible
for the presence of high amplitude electrograms noted during
VF in our subject.
Various mechanisms have been invoked for high ampli-
tude regular intracardiac electrograms during episodes of VF
with chaotic activity noted on the surface ECG. These include -
regional differences in refractory period of cardiac tissue and
conduction blocks in certain regions of the myocardium dur-
ing VF. It is possible that in our subject the relative difference
in myocardial hypertrophy between the left and right ventri-
cles might have resulted in heterogeneity of refractoriness.
This might have been responsible for slower, higher ampli-
tude ventricular activity in the right ventricle and simulta-
neous chaotic, disorganized fibrillatory activity in the left
ventricle. Also, the asymmetric septal hypertrophy noted in
our subject might have caused functional conduction block
between the left and right ventricles manifesting as electrical
heterogeneity during the clinical event [1].
Undersensing of VF in the setting of HCM has been previ-
ously reported. In a subject with HCM, large amplitude oscil-
lation of electrograms and a Boston Scientific device, lowering
the AGC from0.43mV 0.18mV led to appropriate sensing of VF
[2]. In our case, lowering the AGC from 0.6 mV to 0.3 mV was
unsuccessful in preventing undersensing during VF. However,
the amplitude of R waves in sinus rhythm was smaller in
Nestor's case report (9 mV) compared to our case (>25 mv),
which could explain VF undersensing in our case. Another
case report presented similar undersensing of VF in a subject
with ischemic cardiomyopathy and large oscillating electro-
grams during defibrillation testing shortly after device
implant. The sinus rhythm R wave amplitude in this case was
18.5 mV [1].In our subject, we decided to add a dual shock coil lead
because of the failure of 41 J shocks during defibrillation
testing. At implant, we positioned the new AICD lead on the
interventricular septum as this site had smaller sensed R
wave voltages (13 mV). The intention was to avoid large
oscillations in electrogram amplitudes during VF episodes.
Finally, we chose to replace the Boston device with a Med-
tronic Protecta device. The algorithm in the Medtronic de-
vice is called “auto adjusting sensitivity” with a V sensitivity
set at 0.3 mV. No undersensing of VF was noted during the
test and the defibrillation threshold was 21 J. A possible
reason for improved VF sensing during the second proce-
dure could be attributed to the fact that the maximum
sensitivity peak is limited to 10 times the programmed
sensitivity value (e.g. 3 mV peak with a V sensitivity of
0.3 mV) in the Medtronic device, Small amplitude electro-
grams are more likely to be sensed following an electrogram
with a low sensitivity peak. This is in contrast to the Boston
Scientific device implanted previously, where the sensitivity
peak is always 75% of the sensed R wave (e.g. 10.5 mV peak
with VF amplitude of 14 mV). Other possible reasons for
adequate sensing noted during the second defibrillation test
include septal AICD lead position with lower sensed R wave
amplitude and lesser oscillation in the electrogram
amplitude.
This case raises the question as to whether defibrillation
testing is required at the time of AICD implant in subjects with
HCM. The largest study of defibrillation testing in subjects
with HCM found that HCM subjects do not have higher defi-
brillation thresholds compared to other AICD populations [3].
However, this study did not report on the prevalence of VF
undersensing. One can speculate that if defibrillation testing
had been performed at the time of implant in our subject. VF
undersensing and high thresholds could have been recog-
nized and managed appropriately. The available evidence
does not support a recommendation for routine defibrillation
testing in subjects undergoing AICD implantation. The Euro-
pean Heart Rhythm Association/Heart Rhythm Society
guideline recommends that the decision to perform defibril-
lation threshold testing should bemade on an individual basis
by the implanting physician based on the relative risks and
benefits in a given subject [4].Conclusions
The presence of intermittent high amplitude electrograms
during episodes of VF in AICDs using the AGC function should
be recognized as a situation that may necessitate in-
terventions to prevent undersensing and consequent delay in
therapy.Disclosures
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